Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
NXP800 yields neither severe thrombocytopenia, nor any responses.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
